Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis

Pharmacotherapy

Volumn 35, Issue 8, 2015, Pages 719-730

  Kale Pradhan, Pramodini B ^a,b   Mihaescu, Anela ^a   Wilhelm, Sheila M ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

eradication; fluoroquinolone; Helicobacter pylori; meta analysis; sequential therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TINIDAZOLE; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; COMPARATIVE EFFECTIVENESS; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; EPIGASTRIC PAIN; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METALLIC TASTE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; DRUG COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI;

ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84939546721     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1614     Document Type: Article

References (37)

1. Fennerty MB, Lieberman DA, Vakil N, Magaret N, Faigel DO, Helfand M,. Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Am Med Assoc J 1999; 159: 1562-6.
2. Blaser MJ, Atherton JC,. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004; 113: 321-33.
3. The European Helicobater Pylori Study Group (EHPSG). Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997; 41: 8-13.
4. Malfertheiner P, Megraud F, O'Morain C, et al., Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
5. Malfertheiner P, Megraud F, O'Morain C, et al., Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
6. Malfertheiner P, Megraud F, O'Morain CA, et al., Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
7. Megraud F, Coenen S, Versporten A, et al., Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
8. Graham D, Shiotani A,. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321-31.
9. Rimbara E, Fischbach L, Graham D,. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011; 8: 79-88.
10. Howden CW,. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2330-8.
11. Vakil N, Megraud F,. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 985-1001.
12. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F,. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007; 56: 475-9.
13. Wu W, Yang Y, Sun G,. Recent Insights into antibiotic resistance in Helicobacter pylori eradication. Gastroenterol Res Pract 2012; 2012: 723183.
14. Fischbach L, Goodman KJ, Feldman M, Aragaki C,. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002; 31: 128.
15. Osata MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham D,. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161: 1217-20.
16. Choi WH, Park D, Oh SJ, et al., Effectiveness of 10 day sequential therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol 2008; 51: 280-4.
17. Romano M, Cuomo A, Gravina AG, et al., Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010; 59: 1465-70.
18. Federico A, Nardone G, Gravina AG, et al., Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012; 143: 55-61.
19. Paoluzi OA, Visconti E, Andrei F, et al., Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol 2010; 44: 261-6.
20. Diaz-Reganon J, Alarcon T, Domingo D, Lopez-Brea M,. Susceptibility of 36 Helicobacter pylori clinical isolates to four-first-line antibiotics and virulence factors. Rev Esp Quimioter 2006; 19: 34-8.
21. Selgrad M, Bornschein J, Malfertheiner P,. Guidelines for treatment of Helicobacter pylori in the East and West. Expert Rev Anti Infect Ther 2011; 9: 581-8.
22. Chey WD, Wong BC,. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
23. Federico A, Gravina AG, Miranda A, Loguercio C, Romano M,. Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol 2014; 20: 665-72.
24. Yaxley J, Chakravarty B,. Helicobacter pylori eradication-an update on the latest therapies. Aust Fam Physician 2014; 43: 301-5.
25. Chuah SK, Tsay FW, Hsu PI, Wu DC,. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17: 3971-5.
26. Chey WD,. Current consensus and remaining questions regarding the diagnosis and treatment of Helicobacter pylori infection. Gastroenterol Hepatol 2012; 8: 623-5.
27. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-41.
28. Jadad AR, Moore RA, Carroll D, et al., Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
29. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre TCC. 2014. Available from http://tech.cochrane.org/revman. Accessed May 5, 2015.
30. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. 2011. Available from http://www.cochrane-handbook.org. Accessed May 5, 2015.
31. Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Uygun A,. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. Eur J Intern Med 2012; 23: 165-8.
32. Seyyedmajidi M, Falaknazi K, Mirsattari D, et al., Correlation between creatinine clearance and Helicobacter pylori infection eradication with sequential and triple therapeutic regimens: a randomised clinical trial. Arab J Gastroenterol 2011; 12: 150-3.
33. Ozdil K, Calhan T, Sahin A, et al., Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication. Hepatogastroenterology 2011; 58: 1148-52.
34. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, et al., Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010; 31: 1077-84.
35. Qian J, Ye F, Zhang J, et al., Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China. Helicobacter 2012; 17: 478-85.
36. Zullo A, De Francesco V, Hassan C, et al., Modified sequential therapy regimens for Helicobacter pylori eradication: a systematic review. Dig Liver Dis 2013; 45: 18-22.
37. Zullo A, Perna F, Hassan C, et al., Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007; 25: 1429-34.